- In Memoriam
- About
- Apply
- People
- Education
- Events
- Articles
-
News
News Fatty Liver Foundation Opens Applications for Year 2 of the Dr. Stephen A. Harrison Patient Advocacy Fellowship Harrison Fellowship Highlights Patient Advocate Engagement at Liver Forum 20 Harrison Fellows Engage at 10th Annual MASH-TAG Conference Harrison Fellows Convene at AASLD’s The Liver Meeting® 2025 The Dr. Stephen A. Harrison Patient Advocacy Fellowship Program on Surfing the MASH Tsunami Fatty Liver Foundation to Introduce Dr. Stephen A. Harrison Patient Advocacy Fellowship at Liver Forum 19 in Paris, France Fatty Liver Foundation Announces Inaugural Cohort of the Dr. Stephen A. Harrison Patient Advocacy Fellowship Fatty Liver Foundation Launches Groundbreaking Patient Advocacy Fellowship Honoring Dr. Stephen A. Harrison
- FAQ
- Contact
Risks and Safety
What are the potential health risks of participating in a clinical trial?
While clinical trials may offer benefits for patients, such as access to new treatments and contributing to medical advancements, there are risks involved with participating in clinical research. Patients may experience side effects, ranging from mild discomfort to more serious complications, depending on the treatment being studied. Additional procedures, like blood tests, imaging, biopsies, or hospital stays, may be required, which can come with their own risks. Further, some treatments being tested in clinical trials may be less effective than current standard options or may have unforeseen long-term effects.
How can risks be minimized and monitored?
Clinical trials follow strict ethical and safety guidelines to protect participants. Several measures are in place to reduce risks. These may include:

- Institutional Review Boards (IRBs): Institutional Review Boards (IRBs): IRBs review and approve all clinical trials to ensure they are ethical, scientifically valid, and that participant risks are minimized. They also monitor trials for any concerns that emerge regarding adherence, including whether researchers follow the approved protocol, obtain proper informed consent, and ensure participant compliance with study requirements such as medication usage and follow-up visits. Adherence is critical for maintaining data integrity, participant safety, and regulatory compliance throughout the trial.
- Data and Safety Monitoring Boards (DSMBs): These independent committees continuously review trial data to assess safety and effectiveness. If significant risks emerge, the DSMB can recommend changes or even stop the trial.
- Medical Monitoring: Researchers and healthcare providers closely track participants' health throughout the study, adjusting treatment plans as needed to ensure safety.
How can informed consent help me understand risks?
Before enrolling in a clinical trial, participants go through an informed consent process, which ensures they fully understand the study’s purpose, procedures, potential risks, and benefits. The informed consent document explains:
- The treatment or intervention being studied
- Possible side effects and risks of participation
- Any additional procedures or hospital visits required
- How participation may impact daily life
- The right to withdraw from the study at any time
By reviewing this document and discussing concerns with the research team, patients can make an informed decision about participation.
Latest
Fatty Liver Foundation Opens Applications for Year 2 of the Dr. Stephen A. Harrison Patient Advocacy Fellowship
Posted by Elena Samsonova on May 11, 2026
Second Cohort Builds on Strong Inaugural Year with Growing Impact in Liver Research and Policy
MAY 11, 2026, BOISE, IDAHO, USA — The Fatty Liver...
Harrison Fellowship Highlights Patient Advocate Engagement at Liver Forum 20
Posted by Elena Samsonova on March 08, 2026
MARCH 6–7, 2026, RESTON, VIRGINIA, USA
The Harrison Fellows Program was featured at Liver Forum 20, a multi-stakeholder meeting convened by the Forum for Collaborative...
Harrison Fellows Convene at AASLD’s The Liver Meeting® 2025
Posted by Elena Samsonova on November 09, 2025
NOVEMBER 6-9, 2025, WASHINGTON, DC, USA
As AASLD’s The Liver Meeting® 2025 (TLM25) concluded, the event marked an important milestone for the Fatty Liver Foundation...